Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Constellation Energy Corp

Ford Motor Company

Verizon

Welltower

Consider these stock and fund picks now that the Federal Reserve's rate-cutting campaign is underway.

Best Stocks to Buy for a Fed Rate Cut

AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is near its lowest point in six years; it may pay to wait for another dip.

Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)

AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robust drug pipeline are bullish going forward.

AbbVie Stock: Keep Calm And Buy The Dip

A splashy recent acquisition by the company might not be panning out.

Why AbbVie Stock Was Getting Mashed on Monday

AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, an experimental treatment for schizophrenia. This setback is notable as AbbVie had invested $8.

AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?

On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.

AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated

Shares of AbbVie (ABBV) plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of Phase 2 clinical trials.

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of competitor Cobenfy in clinical trials in schizophrenia patients. Emraclidine was the main reason AbbVie acquired Cerevel for $8.7 billion, and I expect a substantial impairment charge on this deal.

AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver

Pharma giant AbbVie Inc has disclosed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. The treatment did not show a significant reduction in the mental illness' symptoms compared to a placebo.

AbbVie sheds $38bn in value after failing schizophrenia drug trials

Bristol-Myers

On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.

AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges

Two trials of the company's experimental schizophrenia drug show no significant improvement in symptoms.

AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' Improvement

AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.

AbbVie's schizophrenia drug misses main goals of two trials

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

Gilead Sciences

Pfizer

High yields aren't a warning indicator with these three stocks.

3 Spectacular High-Yield Dividend Stocks to Buy in November

This Dividend King truly wears the crown.

My Favorite Dividend King to Buy in November

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?

Chevron

e.l.f. Beauty

US stocks remain resilient following the Federal Reserve's decision to lower its key interest rate by another 25 basis points on Thursday. According to the post-meeting statement: The Committee judges that the risks of achieving its employment and inflation goals are roughly in balance.

Top 3 stocks to buy after Fed's 25-basis-point rate cut

Walmart

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

2 Dividend Kings That Would Have Doubled Your Money in 5 Years

Comfort Systems USA

Visa

Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.

Dividend Watch: Three Companies Boosting Quarterly Payouts

Roche Holding AG

Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a better bang for their buck right now?

RHHBY or ABBV: Which Is the Better Value Stock Right Now?

Last Year, BOTOX® Cosmetic Day Set the Record for the Most BOTOX® Cosmetic Gift Cards Sold in a Single Day1 This Year, the Excitement Continues with New Offers to Refer a Friend Plus the Best-Selling Buy-One-Get-One (BOGO) Free Gift Card Offer Join Allē Today to Take Advantage of Exclusive Offers IRVINE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that the sixth annual BOTOX® Cosmetic Day will be Wednesday, November 20.

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

The story with AbbVie NYSE: ABBV in 2024 is that it fell off a patent cliff but survived. It survived and continues to thrive because of its strengths in its core immunology portfolio and diversification efforts.

High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight

Associated Banc-Corp

Berry Global Group

ConocoPhillips

Huntington Ingalls Industries

Investors may keep a tab on stocks like COP, BERY, HII, ABBV and ASB, which have lately hiked their dividend payments.

5 Stocks That Recently Announced Dividend Hikes

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer

News for AbbVie Stock (ABBV)